X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PFIZER - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PFIZER DIVIS LABORATORIES/
PFIZER
 
P/E (TTM) x 30.0 31.4 95.6% View Chart
P/BV x 5.2 5.0 104.1% View Chart
Dividend Yield % 1.0 0.6 146.9%  

Financials

 DIVIS LABORATORIES   PFIZER
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
PFIZER
Mar-16
DIVIS LABORATORIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,2222,724 44.9%   
Low Rs7841,611 48.7%   
Sales per share (Unadj.) Rs153.1440.9 34.7%  
Earnings per share (Unadj.) Rs39.948.7 82.0%  
Cash flow per share (Unadj.) Rs44.675.8 58.9%  
Dividends per share (Unadj.) Rs10.0015.00 66.7%  
Dividend yield (eoy) %1.00.7 144.1%  
Book value per share (Unadj.) Rs201.8462.9 43.6%  
Shares outstanding (eoy) m265.4745.75 580.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.64.9 133.3%   
Avg P/E ratio x25.144.5 56.4%  
P/CF ratio (eoy) x22.528.6 78.6%  
Price / Book Value ratio x5.04.7 106.2%  
Dividend payout %25.030.8 81.3%   
Avg Mkt Cap Rs m266,26699,163 268.5%   
No. of employees `0009.72.9 337.0%   
Total wages/salary Rs m4,6872,758 170.0%   
Avg. sales/employee Rs Th4,175.06,981.7 59.8%   
Avg. wages/employee Rs Th481.5954.5 50.4%   
Avg. net profit/employee Rs Th1,089.3771.1 141.3%   
INCOME DATA
Net Sales Rs m40,64320,170 201.5%  
Other income Rs m749857 87.3%   
Total revenues Rs m41,39221,028 196.8%   
Gross profit Rs m14,4604,310 335.5%  
Depreciation Rs m1,2331,239 99.6%   
Interest Rs m235 434.6%   
Profit before tax Rs m13,9533,923 355.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m3,3491,794 186.6%   
Profit after tax Rs m10,6042,228 476.0%  
Gross profit margin %35.621.4 166.5%  
Effective tax rate %24.045.7 52.5%   
Net profit margin %26.111.0 236.2%  
BALANCE SHEET DATA
Current assets Rs m40,10516,299 246.1%   
Current liabilities Rs m6,5957,594 86.8%   
Net working cap to sales %82.543.2 191.0%  
Current ratio x6.12.1 283.4%  
Inventory Days Days11965 181.6%  
Debtors Days Days8126 313.3%  
Net fixed assets Rs m19,9958,622 231.9%   
Share capital Rs m531458 116.0%   
"Free" reserves Rs m53,04320,722 256.0%   
Net worth Rs m53,57421,180 252.9%   
Long term debt Rs m025 0.0%   
Total assets Rs m61,58529,137 211.4%  
Interest coverage x618.4755.5 81.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.70.7 95.3%   
Return on assets %17.37.7 225.2%  
Return on equity %19.810.5 188.2%  
Return on capital %26.119.0 137.4%  
Exports to sales %00.1 0.0%   
Imports to sales %25.217.5 144.4%   
Exports (fob) Rs mNA12 0.0%   
Imports (cif) Rs m10,2593,526 291.0%   
Fx inflow Rs m35,38452 68,507.0%   
Fx outflow Rs m10,399140 7,428.7%   
Net fx Rs m24,985-88 -28,286.2%   
CASH FLOW
From Operations Rs m11,4933,436 334.5%  
From Investments Rs m-11,372-6,991 162.7%  
From Financial Activity Rs m-93-619 15.0%  
Net Cashflow Rs m28-4,174 -0.7%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 11.8 7.5 157.3%  
FIIs % 19.0 4.9 387.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 23.7 72.6%  
Shareholders   31,796 85,207 37.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 16, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS